Vigonvita Life Sciences Co., Ltd. (HKG:2630)
Hong Kong
· Delayed Price · Currency is HKD
102.20
+0.20 (0.20%)
Last updated: Mar 10, 2026, 11:11 AM HKT
Vigonvita Life Sciences Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 |
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
| Revenue | 11.83 | 199.65 |
| Revenue Growth (YoY) | -94.07% | - |
| Cost of Revenue | 8.35 | 6.01 |
| Gross Profit | 3.49 | 193.64 |
| Selling, General & Admin | 69.39 | 52.51 |
| Research & Development | 134.86 | 131.3 |
| Operating Expenses | 207.15 | 186.39 |
| Operating Income | -203.66 | 7.25 |
| Interest Expense | -16.16 | -7.2 |
| Interest & Investment Income | 0.71 | 1.79 |
| Currency Exchange Gain (Loss) | 0.24 | 0.25 |
| Other Non Operating Income (Expenses) | 1.21 | 4.34 |
| EBT Excluding Unusual Items | -217.67 | 6.43 |
| Gain (Loss) on Sale of Investments | 0.22 | - |
| Gain (Loss) on Sale of Assets | -0.04 | - |
| Other Unusual Items | -0.16 | - |
| Pretax Income | -217.64 | 6.43 |
| Earnings From Continuing Operations | -217.64 | 6.43 |
| Minority Interest in Earnings | 6.24 | 5.66 |
| Net Income | -211.4 | 12.09 |
| Net Income to Common | -211.4 | 12.09 |
| Shares Outstanding (Basic) | 146 | 145 |
| Shares Outstanding (Diluted) | 146 | 145 |
| Shares Change (YoY) | 0.69% | - |
| EPS (Basic) | -1.45 | 0.08 |
| EPS (Diluted) | -1.45 | 0.08 |
| Free Cash Flow | -186.53 | -56.05 |
| Free Cash Flow Per Share | -1.28 | -0.39 |
| Gross Margin | 29.47% | 96.99% |
| Operating Margin | -1721.30% | 3.63% |
| Profit Margin | -1786.71% | 6.05% |
| Free Cash Flow Margin | -1576.46% | -28.07% |
| EBITDA | -183.23 | 14.12 |
| EBITDA Margin | - | 7.07% |
| D&A For EBITDA | 20.44 | 6.87 |
| EBIT | -203.66 | 7.25 |
| EBIT Margin | - | 3.63% |
Source: S&P Capital IQ. Standard template.
Financial Sources.